Not getting enough sleep does more than make you tired. Here’s how short nights can quietly raise your blood pressure, and ...

AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...

CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...

Rising chronic kidney disease prevalence and morbidity rates in 2023 make CKD the ninth leading cause of death globally, ...

A real-world analysis published in JACC Advances concludes that heart failure patients prescribed ivabradine face a significantly higher risk of developing atrial fibrillation (AF) within 180 ...

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.

AstraZeneca Pharma and Sun Pharma have announced an exclusive partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands, aiming to expand patient access across India ...

AstraZeneca Pharma India and Sun Pharma partner to help patients living with hyperkalaemia in India: Our Bureau, Bengaluru Monday, November 17, 2025, 17:20 Hrs [IST] AstraZeneca P ...

Add important vitamins including A, B6, B12, C and more to your diet through foods and supplements for better heart health, ...

On Tuesday, shares of AstraZeneca Pharma India surged following the announcement of an exciting alliance with Sun ...